Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
35
TXG Quote, Financials, Valuation and Earnings
Last price:
$18.87
Seasonality move
:
-23.7%
Day range:
$18.77 - $19.89
52-week range:
$6.78 - $23.56
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.73x
P/B ratio:
3.08x
Volume:
2.4M
Avg. volume:
2.8M
1-year change:
63.32%
Market cap:
$2.5B
Revenue:
$642.8M
EPS (TTM):
-$0.35
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TXG
10X Genomics, Inc.
|
$160.4M | -$0.04 | -5.38% | -77.4% | $19.36 |
|
AMS
American Shared Hospital Services
|
$8.8M | $0.02 | -3.19% | -100% | $4.50 |
|
NVOS
Novo Integrated Sciences, Inc.
|
-- | -- | -- | -- | -- |
|
OMCL
Omnicell, Inc.
|
$313.4M | $0.50 | 12.73% | 46.78% | $57.43 |
|
PFHO
Pacific Health Care Organization, Inc.
|
-- | -- | -- | -- | -- |
|
WW
WW International
|
$180.3M | -$0.29 | -9.38% | -78.02% | $1.10 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TXG
10X Genomics, Inc.
|
$19.19 | $19.36 | $2.5B | -- | $0.00 | 0% | 3.73x |
|
AMS
American Shared Hospital Services
|
$2.12 | $4.50 | $13.9M | 11.73x | $0.00 | 0% | 0.47x |
|
NVOS
Novo Integrated Sciences, Inc.
|
$0.0035 | -- | $69.1K | -- | $0.00 | 0% | 0.00x |
|
OMCL
Omnicell, Inc.
|
$38.63 | $57.43 | $1.7B | 894.21x | $0.00 | 0% | 1.50x |
|
PFHO
Pacific Health Care Organization, Inc.
|
$1.3200 | -- | $16.9M | 11.67x | $0.10 | 0% | 2.53x |
|
WW
WW International
|
$0.25 | $1.10 | $20M | -- | $0.00 | 0% | 0.03x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TXG
10X Genomics, Inc.
|
9.58% | 3.181 | 4.05% | 3.72x |
|
AMS
American Shared Hospital Services
|
50.05% | 0.206 | 110.57% | 1.02x |
|
NVOS
Novo Integrated Sciences, Inc.
|
12.88% | 31.557 | 31.81% | 0.28x |
|
OMCL
Omnicell, Inc.
|
13.51% | 0.525 | 9.46% | 0.98x |
|
PFHO
Pacific Health Care Organization, Inc.
|
-- | 0.605 | 0.24% | 28.77x |
|
WW
WW International
|
381.58% | 0.809 | 3821.84% | 0.14x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TXG
10X Genomics, Inc.
|
$115M | -$14.9M | -5.19% | -5.77% | -8.96% | $39M |
|
AMS
American Shared Hospital Services
|
$1.6M | $48K | -6.67% | -12.09% | 0.67% | -$2M |
|
NVOS
Novo Integrated Sciences, Inc.
|
$1.3M | -$1.5M | -44.59% | -49.15% | -47.07% | -$1.7M |
|
OMCL
Omnicell, Inc.
|
$130.3M | $415K | 0.13% | 0.17% | 0.13% | $15.9M |
|
PFHO
Pacific Health Care Organization, Inc.
|
$714.7K | $205K | 11.97% | 11.97% | 12.92% | $23K |
|
WW
WW International
|
$132.9M | $7.3M | -20.78% | -- | -12.01% | $11.8M |
10X Genomics, Inc. vs. Competitors
-
Which has Higher Returns TXG or AMS?
American Shared Hospital Services has a net margin of -9.79% compared to 10X Genomics, Inc.'s net margin of -4.59%. 10X Genomics, Inc.'s return on equity of -5.77% beat American Shared Hospital Services's return on equity of -12.09%.
Company Gross Margin Earnings Per Share Invested Capital TXG10X Genomics, Inc.69.27% -$0.13 $880.7M AMSAmerican Shared Hospital Services21.94% -$0.00 $53.2M -
What do Analysts Say About TXG or AMS?
10X Genomics, Inc. has a consensus price target of $19.36, signalling upside risk potential of 0.87%. On the other hand American Shared Hospital Services has an analysts' consensus of $4.50 which suggests that it could grow by 112.26%. Given that American Shared Hospital Services has higher upside potential than 10X Genomics, Inc., analysts believe American Shared Hospital Services is more attractive than 10X Genomics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TXG10X Genomics, Inc.4 12 0 AMSAmerican Shared Hospital Services0 0 0 -
Is TXG or AMS More Risky?
10X Genomics, Inc. has a beta of 2.244, which suggesting that the stock is 124.385% more volatile than S&P 500. In comparison American Shared Hospital Services has a beta of 0.147, suggesting its less volatile than the S&P 500 by 85.268%.
-
Which is a Better Dividend Stock TXG or AMS?
10X Genomics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. American Shared Hospital Services offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 10X Genomics, Inc. pays -- of its earnings as a dividend. American Shared Hospital Services pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TXG or AMS?
10X Genomics, Inc. quarterly revenues are $166M, which are larger than American Shared Hospital Services quarterly revenues of $7.2M. 10X Genomics, Inc.'s net income of -$16.3M is lower than American Shared Hospital Services's net income of -$329K. Notably, 10X Genomics, Inc.'s price-to-earnings ratio is -- while American Shared Hospital Services's PE ratio is 11.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 10X Genomics, Inc. is 3.73x versus 0.47x for American Shared Hospital Services. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TXG10X Genomics, Inc.3.73x -- $166M -$16.3M AMSAmerican Shared Hospital Services0.47x 11.73x $7.2M -$329K
-
Which has Higher Returns TXG or NVOS?
Novo Integrated Sciences, Inc. has a net margin of -9.79% compared to 10X Genomics, Inc.'s net margin of -86.61%. 10X Genomics, Inc.'s return on equity of -5.77% beat Novo Integrated Sciences, Inc.'s return on equity of -49.15%.
Company Gross Margin Earnings Per Share Invested Capital TXG10X Genomics, Inc.69.27% -$0.13 $880.7M NVOSNovo Integrated Sciences, Inc.41.76% -$0.16 $25.2M -
What do Analysts Say About TXG or NVOS?
10X Genomics, Inc. has a consensus price target of $19.36, signalling upside risk potential of 0.87%. On the other hand Novo Integrated Sciences, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that 10X Genomics, Inc. has higher upside potential than Novo Integrated Sciences, Inc., analysts believe 10X Genomics, Inc. is more attractive than Novo Integrated Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TXG10X Genomics, Inc.4 12 0 NVOSNovo Integrated Sciences, Inc.0 0 0 -
Is TXG or NVOS More Risky?
10X Genomics, Inc. has a beta of 2.244, which suggesting that the stock is 124.385% more volatile than S&P 500. In comparison Novo Integrated Sciences, Inc. has a beta of 1.479, suggesting its more volatile than the S&P 500 by 47.909%.
-
Which is a Better Dividend Stock TXG or NVOS?
10X Genomics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novo Integrated Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 10X Genomics, Inc. pays -- of its earnings as a dividend. Novo Integrated Sciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TXG or NVOS?
10X Genomics, Inc. quarterly revenues are $166M, which are larger than Novo Integrated Sciences, Inc. quarterly revenues of $3.2M. 10X Genomics, Inc.'s net income of -$16.3M is lower than Novo Integrated Sciences, Inc.'s net income of -$2.7M. Notably, 10X Genomics, Inc.'s price-to-earnings ratio is -- while Novo Integrated Sciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 10X Genomics, Inc. is 3.73x versus 0.00x for Novo Integrated Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TXG10X Genomics, Inc.3.73x -- $166M -$16.3M NVOSNovo Integrated Sciences, Inc.0.00x -- $3.2M -$2.7M
-
Which has Higher Returns TXG or OMCL?
Omnicell, Inc. has a net margin of -9.79% compared to 10X Genomics, Inc.'s net margin of -0.65%. 10X Genomics, Inc.'s return on equity of -5.77% beat Omnicell, Inc.'s return on equity of 0.17%.
Company Gross Margin Earnings Per Share Invested Capital TXG10X Genomics, Inc.69.27% -$0.13 $880.7M OMCLOmnicell, Inc.41.51% -$0.05 $1.4B -
What do Analysts Say About TXG or OMCL?
10X Genomics, Inc. has a consensus price target of $19.36, signalling upside risk potential of 0.87%. On the other hand Omnicell, Inc. has an analysts' consensus of $57.43 which suggests that it could grow by 48.66%. Given that Omnicell, Inc. has higher upside potential than 10X Genomics, Inc., analysts believe Omnicell, Inc. is more attractive than 10X Genomics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TXG10X Genomics, Inc.4 12 0 OMCLOmnicell, Inc.6 1 0 -
Is TXG or OMCL More Risky?
10X Genomics, Inc. has a beta of 2.244, which suggesting that the stock is 124.385% more volatile than S&P 500. In comparison Omnicell, Inc. has a beta of 0.776, suggesting its less volatile than the S&P 500 by 22.402%.
-
Which is a Better Dividend Stock TXG or OMCL?
10X Genomics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Omnicell, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 10X Genomics, Inc. pays -- of its earnings as a dividend. Omnicell, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TXG or OMCL?
10X Genomics, Inc. quarterly revenues are $166M, which are smaller than Omnicell, Inc. quarterly revenues of $314M. 10X Genomics, Inc.'s net income of -$16.3M is lower than Omnicell, Inc.'s net income of -$2M. Notably, 10X Genomics, Inc.'s price-to-earnings ratio is -- while Omnicell, Inc.'s PE ratio is 894.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 10X Genomics, Inc. is 3.73x versus 1.50x for Omnicell, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TXG10X Genomics, Inc.3.73x -- $166M -$16.3M OMCLOmnicell, Inc.1.50x 894.21x $314M -$2M
-
Which has Higher Returns TXG or PFHO?
Pacific Health Care Organization, Inc. has a net margin of -9.79% compared to 10X Genomics, Inc.'s net margin of 14.05%. 10X Genomics, Inc.'s return on equity of -5.77% beat Pacific Health Care Organization, Inc.'s return on equity of 11.97%.
Company Gross Margin Earnings Per Share Invested Capital TXG10X Genomics, Inc.69.27% -$0.13 $880.7M PFHOPacific Health Care Organization, Inc.45.04% $0.02 $12.8M -
What do Analysts Say About TXG or PFHO?
10X Genomics, Inc. has a consensus price target of $19.36, signalling upside risk potential of 0.87%. On the other hand Pacific Health Care Organization, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that 10X Genomics, Inc. has higher upside potential than Pacific Health Care Organization, Inc., analysts believe 10X Genomics, Inc. is more attractive than Pacific Health Care Organization, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TXG10X Genomics, Inc.4 12 0 PFHOPacific Health Care Organization, Inc.0 0 0 -
Is TXG or PFHO More Risky?
10X Genomics, Inc. has a beta of 2.244, which suggesting that the stock is 124.385% more volatile than S&P 500. In comparison Pacific Health Care Organization, Inc. has a beta of 0.126, suggesting its less volatile than the S&P 500 by 87.368%.
-
Which is a Better Dividend Stock TXG or PFHO?
10X Genomics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pacific Health Care Organization, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.10 per share. 10X Genomics, Inc. pays -- of its earnings as a dividend. Pacific Health Care Organization, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TXG or PFHO?
10X Genomics, Inc. quarterly revenues are $166M, which are larger than Pacific Health Care Organization, Inc. quarterly revenues of $1.6M. 10X Genomics, Inc.'s net income of -$16.3M is lower than Pacific Health Care Organization, Inc.'s net income of $223K. Notably, 10X Genomics, Inc.'s price-to-earnings ratio is -- while Pacific Health Care Organization, Inc.'s PE ratio is 11.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 10X Genomics, Inc. is 3.73x versus 2.53x for Pacific Health Care Organization, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TXG10X Genomics, Inc.3.73x -- $166M -$16.3M PFHOPacific Health Care Organization, Inc.2.53x 11.67x $1.6M $223K
-
Which has Higher Returns TXG or WW?
WW International has a net margin of -9.79% compared to 10X Genomics, Inc.'s net margin of -38.91%. 10X Genomics, Inc.'s return on equity of -5.77% beat WW International's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TXG10X Genomics, Inc.69.27% -$0.13 $880.7M WWWW International71.22% -$0.91 $420.1M -
What do Analysts Say About TXG or WW?
10X Genomics, Inc. has a consensus price target of $19.36, signalling upside risk potential of 0.87%. On the other hand WW International has an analysts' consensus of $1.10 which suggests that it could grow by 340.71%. Given that WW International has higher upside potential than 10X Genomics, Inc., analysts believe WW International is more attractive than 10X Genomics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TXG10X Genomics, Inc.4 12 0 WWWW International0 1 0 -
Is TXG or WW More Risky?
10X Genomics, Inc. has a beta of 2.244, which suggesting that the stock is 124.385% more volatile than S&P 500. In comparison WW International has a beta of 1.298, suggesting its more volatile than the S&P 500 by 29.755%.
-
Which is a Better Dividend Stock TXG or WW?
10X Genomics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. WW International offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 10X Genomics, Inc. pays -- of its earnings as a dividend. WW International pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TXG or WW?
10X Genomics, Inc. quarterly revenues are $166M, which are smaller than WW International quarterly revenues of $186.6M. 10X Genomics, Inc.'s net income of -$16.3M is higher than WW International's net income of -$72.6M. Notably, 10X Genomics, Inc.'s price-to-earnings ratio is -- while WW International's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 10X Genomics, Inc. is 3.73x versus 0.03x for WW International. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TXG10X Genomics, Inc.3.73x -- $166M -$16.3M WWWW International0.03x -- $186.6M -$72.6M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
32
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Sell
49
FROG alert for Feb 21
JFrog Ltd. [FROG] is down 24.98% over the past day.
Buy
73
HYMC alert for Feb 21
Hycroft Mining Holding Corp. [HYMC] is down 2.47% over the past day.
Buy
62
OMC alert for Feb 21
Omnicom Group, Inc. [OMC] is up 2.87% over the past day.
